ImmunityBio

Early detection can be simple: pay attention to what feels different.

Blood in the urine, a shift in frequency, discomfort that lingers; these signs may seem easy to dismiss,
but recognizing them can expand the opportunity for timely evaluation and improved outcomes.

ImmunityBio's relentless pursuit of groundbreaking therapies underscores our commitment to delivering hope and better solutions for patients with bladder cancer.

We’re heading to ASCO 2026.

We’re looking forward to joining researchers, clinicians, advocates, and industry partners united by a shared goal: improving outcomes for people impacted by cancer. Our team values the opportunity to collaborate and continue advancing patient-focused innovation alongside the broader oncology
community.

Visit us at booth #27131 to connect with the ImmunityBio team.

Behind every bladder cancer diagnosis is a person navigating uncertainty, complex decisions, and changes to their daily lifestyle. Organizations like Bladder Cancer Advocacy Network (BCAN) help ensure that affected individuals have access to information, support, and a community that understands what they're facing.

Learn more about BCAN's resources for patients and caregivers: https://bcan.org/

ImmunityBio announced that the U.S. Food and Drug Administration (FDA) has accepted for review the supplemental Biologics License Application of its bladder cancer therapy in combination with Bacillus Calmette-Guerin (BCG) for patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with papillary disease without carcinoma in situ.

Learn more:

ImmunityBio Announces FDA Acceptance of Supplemental BLA for ANKTIVA® Plus BCG in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer with Papillary Disease; PDUFA Date Set for January 6, 2027 - ImmunityBio CULVER CITY, Calif.–(BUSINESS WIRE)–May 19, 2026– ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced that the U.S. Food and Drug Administration has accepted for review the supplemental Biologics License Application (sBLA) for ANKTIVA® (nogapendekin alf...

At the heart of every advancement are the people who make it possible.

Our focus is on bringing in individuals who are collaborative, solution-oriented, and motivated by work that carries broader significance. View our open roles: https://immunitybio.com/careers/

At , our Founder, Executive Chairman and Global Chief Scientific and Medical Officer, Dr. Patrick Soon-Shiong, took center stage to address several of the most pressing challenges facing the bladder cancer community today: the continued impact of BCG shortages and ImmunityBio's efforts to help advance new supply solutions to the broader need for sustainable innovation across the field.

The discussion reinforced an important reality: progressing bladder cancer care requires more than scientific progress alone. It also demands long-term commitment, collaboration, and practical solutions that help ensure patients can reliably access the therapies they need.

ImmunityBio has announced an exclusive U.S. Development and Supply Agreement with Japan BCG Laboratory for the development and commercialization of Tokyo strain BCG in the U.S.

Today's announcement marks a notable step forward in addressing the ongoing BCG shortage that has impacted urologists and bladder cancer patients for more than a decade.

Learn more:

ImmunityBio Signs Exclusive U.S. Agreement with Japan BCG Laboratory for the Tokyo Strain of BCG to Enhance BCG Supply in the United States - ImmunityBio WASHINGTON, May 16, 2026 — ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced an exclusive U.S. Development and Supply Agreement with Japan BCG Laboratory (“JBL”), the Tokyo-based developer and manufacturer of the Tokyo strain of BCG (Tokyo-172 BCG). Th...

Bladder cancer continues to impact tens of thousands of individuals each year. Increasing awareness of the disease - and recognizing changes early - can play an important role in improving outcomes.

ImmunityBio remains committed to supporting the patients, caregivers, and healthcare providers impacted.